Johnson & Johnson (NYSE:JNJ) Holdings Reduced by Mawer Investment Management Ltd.

Key Points

• Mawer Investment Management Ltd. decreased its stake in Johnson & Johnson by 2.4%, owning 498,598 shares valued at approximately $82.69 million after selling 12,338 shares in the first quarter.
• Johnson & Johnson reported $2.77 earnings per share for the last quarter, surpassing analysts' estimates, with revenue increasing by 5.8% year-over-year to $23.74 billion.
• The firm announced a quarterly dividend of $1.30 per share, yielding 3.13%, with a payout ratio of 55.61%, highlighting its commitment to returning value to shareholders.

Mawer Investment Management Ltd. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 498,598 shares of the company's stock after selling 12,338 shares during the period. Mawer Investment Management Ltd.'s holdings in Johnson & Johnson were worth $82,687,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. Lantz Financial LLC grew its stake in Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after acquiring an additional 377 shares during the period. Sulzberger Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $453,000. Joel Isaacson & Co. LLC grew its stake in shares of Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after buying an additional 2,526 shares during the period. State of Wyoming grew its stake in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after buying an additional 10,279 shares during the period. Finally, Range Financial Group LLC grew its stake in shares of Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after buying an additional 2,529 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.5%

Shares of Johnson & Johnson stock traded up $2.43 during trading on Friday, reaching $167.17. The company had a trading volume of 5,337,337 shares, compared to its average volume of 9,049,290. The company has a market cap of $402.61 billion, a price-to-earnings ratio of 17.88, a price-to-earnings-growth ratio of 2.13 and a beta of 0.41. The firm's fifty day moving average is $157.18 and its 200-day moving average is $156.44. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the business posted $2.82 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.